P. A. Crossey, F. M. Richards, K. Foster, J. S. Green, A. Prowse, F. Latif, M. I. Lerman, B. Zbar, N. A. Affara, M. A. Ferguson-Smith, and R. Maher, (1994) Buys CHCM, identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype, Hum. Mol. Genet., 3, 1303-1308.

has been cited by the following article:

• TITLE: Descriptively probabilistic relationship between mutated primary structure of von Hippel-Lindau protein and its clinical outcome

  AUTHORS: Shao-Min Yan, Guang Wu

  KEYWORDS: Amino Acid; Bayes’ Law; Cross-Impact Analysis; Distribution Probability; Mutation; Von Hip-pel-Lindau Disease

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.2 No.3, May 27, 2009

  ABSTRACT: In this study, we use the cross-impact analysis to build a descriptively probabilistic relationship between mutant von Hippel-Lindau protein and its clinical outcome after quantifying mutant von Hippel-Lindau proteins with the amino-acid distribution probability, then we use the Bayes-ian equation to determine the probability that the von Hippel-Lindau disease occurs under a mutation, and finally we attempt to distinguish the classifications of clinical outcomes as well as the endocrine and nonendocrine neoplasia induced by mutations of von Hippel-Lindau protein. The results show that a patient has 9/10 chance of being von Hippel-Lindau disease when a new mutation occurs in von Hippel- Lindau protein, the possible distinguishing of classifications of clinical outcomes using mod-eling, and the explanation of the endocrine and nonendocrine neoplasia in modeling view.